Filtros de búsqueda

Lista de obras de

A common Greenlandic Inuit BRCA1 RING domain founder mutation

artículo científico publicado en 2008

A high frequent BRCA1 founder mutation identified in the Greenlandic population

artículo científico publicado en 2009

A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis

artículo científico publicado en 2017

A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers

artículo científico publicado en 2012

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy ⬇️

artículo científico publicado el 31 de julio de 2012

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

artículo científico publicado en 2017

Adjuvant chemotherapy in early breast cancer

artículo científico publicado en 2016

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.

artículo científico publicado en 2008

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

artículo científico publicado en 2012

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

artículo científico

Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes

artículo científico publicado en 2004

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

artículo científico publicado en 2009

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

artículo científico publicado en 2015

Aromatase inhibitors in the treatment of early and advanced breast cancer

artículo científico publicado en 2005

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers

artículo científico publicado en 2015

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

artículo científico publicado en 2011

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.

artículo científico publicado en 2016

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

artículo científico publicado en 2012

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

artículo científico publicado en 2015

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2014

Associations of parity-related reproductive histories with ER± and HER2± receptor-specific breast cancer aetiology

artículo científico publicado en 2017

Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer

artículo científico publicado en 2017

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

artículo científico publicado en 2008

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.

artículo científico publicado en 2016

Breast conserving surgery versus mastectomy: overall and relative survival-a population based study by the Danish Breast Cancer Cooperative Group (DBCG).

artículo científico publicado en 2017

Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2014

Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort

artículo científico publicado en 2017

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

artículo científico publicado en 2013

Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark

artículo científico publicado en 2018

Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark

scholarly article by Lindsay J Collin et al published 1 August 2018 in BMJ Open

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2011

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

artículo científico publicado en 2011

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evalu

artículo científico publicado en 2017

Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database

artículo científico publicado en 2017

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer

artículo científico publicado en 2010

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity

artículo científico publicado en 2016

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients

artículo científico publicado en 2008

DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2014

Danish Breast Cancer Cooperative Group

artículo científico publicado en 2016

Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark ⬇️

artículo científico publicado el 13 de junio de 2013

ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry

artículo científico

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial ⬇️

artículo científico publicado el 15 de enero de 2011

Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study

artículo científico publicado en 2007

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

artículo científico

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

artículo científico publicado en 2017

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

artículo científico publicado en 2018

Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer

artículo científico publicado en 2013

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

artículo científico publicado en 2016

Functional characterization of BRCA1 gene variants by mini-gene splicing assay

artículo científico publicado en 2014

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

artículo científico publicado en 2016

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

artículo científico publicado en 2013

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2010

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

article

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

artículo científico publicado en 2013

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

artículo científico publicado en 2011

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients

artículo científico

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

artículo científico publicado en 2015

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial

artículo científico publicado en 2016

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

artículo científico publicado en 2017

Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations

artículo científico publicado en 2010

Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for br

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

artículo científico publicado en 2016

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

artículo científico publicado en 2016

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

artículo científico publicado en 2015

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer

artículo científico publicado en 2016

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

artículo científico publicado en 2017

Importance of margin width in breast-conserving treatment of early breast cancer

artículo científico publicado en 2016

Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment

artículo científico publicado en 2016

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

artículo científico publicado en 2009

Incidence of metachronous contralateral breast cancer in Denmark 1978-2009.

artículo científico

Is DBCG abreast of new developments?

artículo científico publicado en 2018

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.

artículo científico publicado en 2009

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status ⬇️

artículo científico publicado el 26 de noviembre de 2011

Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families

artículo científico publicado en 2008

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

artículo científico publicado en 2015

Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer

artículo científico publicado en 2012

Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence

artículo científico publicado en 2016

Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study

artículo científico publicado en 2018

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

artículo científico publicado en 2016

Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark ⬇️

artículo científico publicado el 31 de agosto de 2011

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

artículo científico publicado en 2017

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

artículo científico publicado en 2013

Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations

artículo científico publicado en 2018

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

artículo científico publicado en 2015

Non-aspirin NSAIDs and contralateral breast cancer risk

artículo científico publicado en 2018

Novel de novo BRCA2 mutation in a patient with a family history of breast cancer

artículo científico publicado en 2008

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial

artículo científico publicado en 2012

Oncoplastic breast surgery does not delay the onset of adjuvant chemotherapy: a population-based study

artículo científico publicado en 2017

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer ⬇️

artículo científico publicado el 8 de junio de 2013

Opioids and breast cancer recurrence: A Danish population-based cohort study

artículo científico publicado en 2015

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

artículo científico publicado en 2012

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

artículo científico publicado en 2018

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

artículo científico

Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer

artículo científico publicado en 2007

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

artículo científico publicado en 2004

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer

artículo científico publicado en 2009

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also

artículo científico publicado en 2015

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group

artículo científico publicado en 2008

Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study

artículo científico publicado en 2015

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy ⬇️

artículo científico publicado el 30 de marzo de 2012

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury

artículo científico publicado en 2014

Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008-2017.

artículo científico publicado en 2017

Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study

artículo científico publicado en 2017

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

artículo científico publicado en 2015

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

artículo científico publicado en 2016

Risk of contralateral breast cancer after tamoxifen use among Danish women

artículo científico

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers

artículo científico publicado en 2015

Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations

artículo científico publicado en 2011

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

artículo científico publicado en 2006

Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"

artículo científico publicado en 2004

Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study

artículo científico publicado en 2010

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

artículo científico publicado en 2014

TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients ⬇️

artículo científico publicado el 9 de diciembre de 2011

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C).

artículo científico publicado en 2008

The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

artículo científico publicado en 2017

The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study

artículo científico publicado en 2015

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.

artículo científico publicado en 2018

The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes

artículo científico publicado en 2017

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

artículo científico publicado en 2011

The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.

artículo científico publicado en 2017

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

artículo científico

The effect of bisphosphonates on pain relief in patients with bone metastases: A status article based on the Cochrane analysis: "Bisphosphonates for the relief of pain secondary to bone metastasis"

artículo científico publicado en 2003

The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study

artículo científico publicado en 2017

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

artículo científico publicado en 2017

Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study

artículo científico publicado en 2017

Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group

artículo científico publicado en 2008

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda